Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership

Taconic Biosciences and Cyagen Biosciences announced a strategic partnership. Under the agreement terms, the two companies will combine resources to provide the global scientific community with access to premium custom model design and generation services backed by comprehensive capabilities and cutting-edge, fully-licensed technologies.

Custom animal models play a critical role in new drug discovery as biological systems that provide critical insight into the dynamic between a potential therapeutic and a living organism.

Combining over twenty years of experience, the industry’s most extensive model generation technology portfolio, and seamless integration to downstream premium custom breeding solutions, Taconic is recognized for creating complex genetically engineered mice and rats for biomedical research. Cyagen entered the industry in 2005 and has gained a strong following for providing model and vector generation services. Through the alliance, Cyagen customers gain access to expanded expertise, comprehensive program management, state-of-the art technologies, pricing flexibility, and faster project timelines through a single point of contact, ensuring the best solution for each unique project.

“Taconic will provide the best solution to every model generation customer through access to scientific experts who generate superior designs using state-of-the-art methods. Through this alliance with Cyagen, Taconic can now offer customers the broadest range of options in the industry in line with market demand,” shared Dr. Robert Rosenthal, CEO of Taconic Biosciences.

“Cyagen Biosciences provides researchers with the highest quality animal models possible to ensure ground breaking discoveries. Researchers are increasingly demanding higher quality animal model services at lower costs. Through this new alliance with Taconic, Cyagen will offer researchers even higher quality animal models, with new options available to minimize or eliminate quarantine and other added costs, while providing production capabilities that exceed previous standards and expectations,” commented Dr. Reza Rezaei, VP of Sales of Cyagen Biosciences.